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Changes in NO activity may play an important role
in the early increase in microvascular flow that
has been implicated in the pathogenesis of dia-
betic microangiopathy. We assessed, in the in situ
spinotrapezius muscle preparation of 6 weeks’
streptozotocin-diabetic rats (n=6) and of age-
matched controls (n 8), basal inside diameters of
A2-A4 arterioles and the reactivity to topically
applied acelcholine and nitroprusside, before
and after NG-nitro-L-arginine. In diabetic rats,
cholinergic vasodilatation in A2-A4 arterioles was
intact. Basal diameter in A3 and A4 arterioles was
significantly higher in streptozotocin-diabetic rats.
The increased basal diameter in A3 arterioles was
partially due to an increased contribution of NO to
basal diameter. The response to nitroprusside was
impaired in streptozotocin-diabetic rats in A2, but
not in A3 and A4 arterioles. Thus, this study shows
that NO activity and sensitivity are altered after 6
weeks of streptozotocin-induced diabetes. These
streptozotocin-induced changes are anatomically
specific and, for arterioles, depend on their position
within the vascular tree.
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INTRODUCTION
Microangiopathy has a major impact on mor-
bidity and mortality of patients with diabetes
mellitus. [1] An important hypothesis regarding
the pathophysiology of diabetic microangio-
pathy is the hemodynamic hypothesis, 21 which
states that an early, reversible increase in micro-
vascular flow eventually leads to an endothelial
injury response and microvascular sclerosis. [2-4]
Using a mathematical model and experimen-
tal data on nitric oxide (NO) production and
degradation rates, Vaughn et al., showed that the
range ofNO actionmay exhibit significant spatial
heterogeneity in vivo and that the microcircula-
tion is the optimal site for NO to exert its
regulatory function. 5, 61 An increased flow early
in diabetes, possibly as a result of enhanced NO
production, has been described in several micro-
vascular beds. I7, 81 However, those studies
*Corresponding author. Department of Internal Medicine, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Tel.:
+31 20 4440629/4440531, Fax: +31 20 4440502, e-mail: cda.stehouwer@azvu.nl
221222 B. VAN DAM et al.
addressed only overall changes in flow. In order
to gain insight in the exact role of NO in micro-
angiopathy, it is necessary to assess its activity
and effectivity at different sites of the microcircu-
lation, as several orders of arterioles can react
differently to chemical and mechanical vasoac-
tive stimuli. 9-11] Recently, it was shown that the
small arterioles that control capillary perfusion
are capable of responding differently in a spatial-
ly organised way and that metabolic changes are
able to change this pattern of diameter change.
[12]
The earliest changes in the microvasculature
caused by the metabolic disturbance in type 1
diabetes can most likely be observed in striated
muscle, which is metabolically the most active
tissue. Indeed, changes in reactions in different
orders of arterioles of striated muscle to several
vasoactive substances have been observed in
rats 6 weeks after the induction of diabetes by
streptozotocin (STZ). [13]
To gain more insight regarding the role of
NO in the pathophysiology of diabetes-induced
microangiopathy, we investigated its contribu-
tion to vascular tone in arcade (A2) arterioles
and the smaller transverse (A3) and precapillary
(A4) arterioles in the in situ spinotrapezius
muscle preparation I14’151 of control rats and
rats with STZ-induced diabetes. We chose the
spinotrapezius muscle because it is easily acces-
sible without much trauma, because different
orders of arterioles can be studied with intravital
microscopy, and because drugs can be applied
topically, thus preventing systemic changes.
The aim of the present study, therefore, was
to assess, in vivo, the contribution of NO to
basal tone and the reactivity to nitroprusside
in different orders of arterioles after 6 weeks of
STZ-induced diabetes, a widely studied model




All experiments were performed according to
the NIH guidelines for the use of experimental
animals (Helsinki declaration), after permission
of the institutional animal care and use commit-
tee. Diabetes was induced in 6 conscious male
Wistar rats (,,250g; HSD, Zeist, The Nether-
lands) by a single tail vein injection of 65mg/kg
STZ dissolved in sodium citrate buffer (pH
4.5). Glucose levels were assessed weekly in
each animal with a haemo-glukotest (Accutrend
Alpha, Boehringer Mannheim) in blood samples
taken from the tail tip. The animals were housed
in individual cages and were allowed free access
to water and pre-weighed commercial rat pellet
chow. Experiments were performed 6 weeks af-
ter administration of STZ. Untreated male Wistar
rats (n 8) were used as controls.
General Set Up
Anesthesia was induced in overnight fasted
rats by an injection of pentobarbital sodium
(NembutalR; 60mg/kg, intraperitoneally) and
ketamine (70mg/kg, intramuscularly). For fur-
ther administration of NembutalR, an intraperi-
toneal cannula was inserted. As an indication
of the need for additional small doses of the
anesthetic (25% of the original dose), we fre-
quently monitored blood pressure, interdigital
and eye reflexes, as well as respiration rate with
the intent of keeping the depth of the anesthesia
stable. In our hands, this anesthetic protocol
caused stable hemodynamics and blood gas
values throughout the entire experimental period
(approximately 5 hrs), indicating a constancy of
the anesthetic conditions. Moreover, in previous
studies E17,181 we have also found a stable 02-
consumption of the animal and low blood lactate
levels throughout the whole experiment. During
the experiment, body temperature was kept at
37-38C by a heating pad placed under the rat.
The trachea was cannulated to maintain a patent
airway.
To be informed about the systemic hemo-
dynamic variables which could influence the
microcirculation we measured cardiac output
in addition to blood pressure. Mean arterial
pressure (MAP) was determined with a catheterNO ACTIVITY AND SENSITWITY 223
(PE50) placed in the right carotid artery. The
heart rate (HR) was obtained from the blood
pressure recording. Cardiac output (CO) was
measured by thermodilution: saline (0.2ml) at
room temperature was injected from a catheter
that was inserted in the right jugular vein, with
the tip near the right atrium. A thermistor,
which was obtained from a Swan-Ganz cathe-
ter (Gould, Cleveland, OH), was inserted into
the abdominal aorta via a femoral artery. The
thermistor was connected to an Edwards 9520A
(Santa Ana, CA) cardiac output computer.
Arterial blood samples were taken from a
carotid artery at the beginning and the end of an
experiment to measure glucose and insulin (by
radioimmunoassay; Immunoradiometric Assay,
Medgenic Diagnostics, Fleurus, Belgium).
5% CO2, to prevent direct oxygenation of the
muscle cells by high levels of oxygen in the
surrounding fluid. Only during the dissection
was this solution equilibrated with 95% 02 and
5% CO2. The temperature of the solution was
maintained at 36C at the muscle surface; the
pH was 7.4.
We used a Zeiss microscope (Zeiss, Germany)
with a 25xSW objective (numerical aperture
0.63; Leitz, Germany). The optical magnification
at the front plane of the video camera was
58.8x. The experiments were recorded on video
tape (Panasonic AG-6200, Japan) using a black
and white Philips LDH 0702/20 camera (Philips,
The Netherlands). Inside diameters of A2-A4
arterioles were measured on the monitor from
stopped images with an interactive computer
program (made in our own workshop).
[22]
Spinotrapezius Preparation
The left spinotrapezius muscle was approached
through a skin incision along the spine, after
which subcutaneous fat and fascia were care-
fully removed. The lateral border of the muscle
was freed and lifted with 4 to 5 atraumatic
sutures to separate it from the underlying mus-
cle layers. It was then draped, with the ventral
surface upward, over a perspex pedestal placed
on the microscope stage (Fig. 1) as described by
Gray I141 and Marshall. I191 A specific area of
interest was selected at the caudo-medial side in
which different orders of arterioles were present.
Classification of the vessels [20,21] is also il-
lustrated in Figure 1. Vessels derived directly
from feeding or A1 arterioles and forming main
arcades are considered A2 arterioles. Vessels
derived from these larger arcade vessels, form-
ing smaller arcades, are considered A3 arte-
rioles. Finally, as A4 arterioles we considered
vessels that supply blood from the smallest
arcades to terminal arterioles.
The muscle was superfused with tyrode
solution (NaC1, 128.3, KC1 4.7, CaC12 H20 1.36,
MgC12.6H20 1.05, NaHCO3 20.2, NaH2PO4.
2H20 0.42mol/L). During the experiment the
superfusate was equilibrated with 95% N2 and
Protocol
After catheterisation of the rat and preparation
of the spinotrapezius muscle had been finished,
we moved the animal to the microscope. After a
suitable arcade had been found, we waited at
least 30min for stabilisation of the preparation
and then started the video microscopic measure-
ments according to the following protocol.
First, the basal inside diameter was assessed.
After that, several drugs were added to the
superfusate, reaching their final concentrations
at the surface of muscle. They were applied until
their effect was maximal (usually for 5 min).
After the diameter had returned to the control
value (after 5-15 min), the next concentration of
a drug was started. The arteriolar inside dia-
meters were recorded before, during, and after
the entire period of superfusion of the drugs.
The integrity of the endothelial vasodilator
response was assessed by testing the effect of
ACh. The experimental set up did not allow us
to perform a complete dose-response relation-
ship of ACh. Therefore, we focused on the
capacity of ACh to dilate the vessels maximally.
We used 3 different doses (10 -5, 10-4 and









FIGURE 1 Experimental set-up of the spinotrapezius preparation. The spinotrapezius muscle is draped over a perspex cylinder
positioned in the microscope stage. The dorso-medial side of the muscle, with intact feeding arterioles, remains connected to the
rat, which lies on its side. The preparation is superfused with Tyrode solution. The microscope is equipped with a video system
to continuously record microvessels on tape. AI: feeding arteriole; A2: main arcade arterioles > 40 tm); A3: smaller arcade
arterioles (2040 tm); A4: arterioles supplying the terminal arterioles (1020 m).
responses, to accurately assess the level of the
maximal response and the dose at which the
maximal response was reached.
After we had tested the effect of ACh, we
administered the NO-generating endothelium-
independent vasodilator nitroprusside (NP:
10-4mol/L, i.e., a dose high enough to cause
maximal dilatation in control animals, as estab-
lished in pilot experiments). Finally, adenosine
(Ad), a mainly endothelium-independent vaso-
dilator was added. [23-25] The dose of Ad to
obtain maximal dilatation was previously as-
sessed at 10-4mol/L; the diameter after appli-
cation of this dose was considered as the passive
diameter and this diameter was set at 100%. This
approach enabled us to relate basal diameters
and the effects of the different drugs to a dia-
meter that was independent from the initial
contractile state.
[26]
After this series, we added L-NNA (10-4mol/
L) to the superfusate to block NO production.
Twenty minutes after the start of L-NNA, inside
diameter was assessed. The contribution of NO
activity to basal diameter was defined as the
percentage reduction in basal diameter that
could be achieved by L-NNA (10-4mol/L). We
repeated the protocol with the dilatory drugs
while L-NNA superfusion continued.
Analysis and Statistics
For statistical evaluation, we used the average
values of all A2, A3, or A4 arterioles (ranging
from 2 to 10) per rat. In 1 STZ rat muscle pre-
paration no A3 arterioles were evaluated; the
number of observations for statistical analysis
was thus 6 for the STZ-treated rats in A2 and A4
arterioles, 5 for the STZ-treated rats in the A3NO ACTWITY AND SENSITWITY 225
arterioles and 8 for the control group. We used
two-tailed non-parametric tests with level of
significance set at 5%.
RESULTS
General Characteristics
Blood glucose level measured 1 week after the
STZ injection was 20 + 5mmol/L and remained
so during the entire period of 6 weeks. Food
consumption in DM rats, compared with con-
trol rats, almost doubled ( 150 vs. 300 g/wk).
Nevertheless, the body weight of DM rats
remained less than that of the control counter-
parts (242+32g vs. 350+36g for 6 weeks’
diabetic rats and control rats, respectively;
P < 0.05). There was no relationship between
body weight and either passive diameter, base-
line diameter or diameter during L-NNA in the
different arterioles (data not shown). Systemic
hemodynamic and biochemical variables at the
start and at the end of the experiments are
presented in Table I. At the day of the experi-
ment, after an overnight fast, the glucose levels
of both the DM and control rats had been
TABLE Systemic variables 24hr before the experiments
(t--- -24hr), at the start of the experiments (t =0) and at the
end of the experiments (t 3 hr) in control and diabetic rats
(DM; six weeks after injection of STZ). Hct: hematocrit;
MAP: mean arterial pressure; HR: heart rate; CO: cardiac
output. Data are expressed as mean + SD
Control (n 8) DM (n 6)
Gluc (mmol/L) t---24hr 5.4 4- 1.1 19.9 4- 1.9"
---0 hr 4.4 4- 0.5 !1.2 4- 2.0*
3 hr 4.5 4- 0.6 10.4 4- 3.5*
Insulin (mU/L) 0 hr 20.6 4- 2.0 8.0 4- 2.0*
Hct 0 hr 49.7 4- 5.8 52.8 4- 2.8
MAP (mmHg) t=0hr 116 4- 17 112 4- 15
3 hr 123 4- 20 124 4- 9
HR (bts/min) 0hr 395 4- 44 340 4- 38*
3 hr 400 4- 24 347 4- 27*
CO (mL/min) =0 hr 98 4- 15 79 4- 14"
3 hr 85 4- 12 64 4- 10"
*P < 0.05 for DM vs. control.
decreased by ,,40% as compared to the non-
fasted state. Baseline blood pressure was not
significantly different between the groups, but
heart rate and cardiac output were significantly
higher in control rats. Hct was not significantly
different between control and diabetic rats.
During the actual microcirculation experiments
(lasting 3 hr), there was a decrease in CO of
about 15% in both control and diabetic rats.
MAP and HR did not change significantly dur-
ing the experiments (Tab. I).
Inside Arteriolar Diameter in Different
Orders of Arterioles
As compared to control rats, DM rats had
significantly increased inside diameters of A3
and A4, but not of A2 arterioles in the basal
state (Fig. 2, Tab. II). Basal diameters relative
to passive diameter did not differ significantly
between DM and control rats (Fig. 2).
Contribution of Endogenous NO
to Basal Inside Diameter
Overall, superfusion of L-NNA (10-4mol/L)
caused a decrease in basal diameter in both con-
trol and diabetic rats (Tab. II), confirming the role
of NO in maintaining basal diameters in this
model. After blockade of the endogenous NO
production, inside arteriolar diameters were not
significantly different in DM rats as compared
with control rats (Tab. II). However, the con-
tribution of NO activity to basal inside diameter
was significantly higher in diabetic rats than in
control rats in A3 arterioles (Fig. 3).
Response to Nitroprusside
After addition of nitroprusside in the basal state,
a significantly higher inside diameter was found
in all types of arterioles in both control and
diabetic rats (Tab. II). However, this increase
was smaller in A2 arterioles of diabetic rats as226 B.w DAM et al.














FIGURE 2 Inside arteriolar diameter in the basal state. Inside diameters, both absolute (tm) and expressed as percentage of the
passive diameter (i.e., after 10-4mol/L adenosine; set at 100%), of A2A4 arterioles in the spinotrapezius muscle at baseline
in control (open plots) and diabetic rats (DM; filled plots). The data are expressed as box-and-whisker plots: the central line is
the median, the lower and upper quartiles are indicated by the box and the 2.5 and 97.5 centiles are indicated by whiskers.
P-values for the comparison between DM and control rats for absolute basal inside diameters: A2, P =0.85; A3, P =0.03; A4,
P 0.03. P-values for the comparison betweenDM and control rats for relative inside diameters: A2, P 0.85; A3, P 0.22; A4,
P =0.14.
compared to controls. By contrast, in A3 arte-
rioles inside diameter remained higher under
nitroprusside in diabetic animals as compared
to controls, while in A4 arterioles similar in-
side diameters were found (Tab. II). In order to
correct for differences in basal NO production,
responses to nitroprusside were also assessed
after addition of L-NNA (Fig-, 4). In contrast
to control rats, in DM rats the response to
10-4mol/L nitroprusside superfusion was sig-
nificantly lower in A2, but not in the A3 and A4
arterioles, when endogenous NO production
was blocked by L-NNA. We have tested in 3
additional experiments whether higher dosesNO ACTIVITY AND SENSITIVITY 227
TABLE II Inside diameters (in lm) of A2, A3 and A4
arterioles in the spinotrapezius of control and diabetic (DM)
rats at baseline, after blocking the NO production with L-
NNA, and after dilatation with 10-4M nitroprusside (NP),
10-3M acetylcholine (ACh) or 10-4M adenosine (Ad). Data
are expressed as mean 4- SD
Order of Control DM
arteriole Condition (n 8) (n 6)
of NP could further increase the arteriolar dia-
meters inDM rats, but this was not the case (data
not shown). Superfusion of higher doses of
NP, however, had a complicating disadvantage,
because at these doses the NP caused systemic
effects (i.e., a decrease in blood pressure).
A2 basal 39.1 4- 11.7 36.5.4- 10.1
L-NNA 10-4M 31.6 4- 9.3 24.2 4- 4.5
NP 10-4M 61.8 4- 11.7 48.9 4- 4.7*
ACh 10-3M 62.4 4- 14.1 54.5 4- 8.9
Ad 10
-4M 63.7 4- 11.8 56.4 4- 6.4
A3 basal 15.5 4- 5.2 23.1 4- 5.5*
L-NNA 10-4M 12.3 4- 3.1 13.6 4- 2.4
NP 10-4M 26.2 4- 4.1 31.6 4- 3.7*
Ach 10-3M 25.4 4- 5.8 32.3 4- 3.0*
Ad 10-4M 27.7 4- 3.5 32.8 4- 2.2*
A4 basal 7.9 4- 2.8 11.6 4- 2.1"
L-NNA 10-4M 6.2 4- 2.7 7.3 4- 3.7
NP 10-4M 15.0 4- 3.1 16.7 4- 4.4
Ach 10-3M 15.2 4- 3.4 15.9 4- 2.8
Ad 10-4M 15.4 4- 3.4 18.0 4- 7.4
*P < 0.05 for DM vs. control.
Responses to Acetylcholine
and Adenosine
Acetylcholine, as compared with adenosine, was
able to cause maximal dilatation in both control
and diabetic rats in all orders of arterioles. No
differences were found between acetylcholine
doses of 10
-4 and 10
-3 mol/L. In A3 arterioles,
inside diameters were significantly higher in
diabetic rats after both after acetylcholine and
adenosine (Tab. II). However, when endogenous
NO production was blocked by L-NNA, inside
diameters after adenosine or acetylcholine were













FIGURE 3 Contribution of endogenous NO to basal inside diameter in different orders of arterioles. Percentage reduction of the basal
diameter ofA2A4 arterioles in the spinotrapezius muscle caused by superfusion ofL-NNA (10-4mol/L) in control (open plots)
and in diabetic rats (DM; filled plots); box-and-whisker plots. P-values for the comparison between DM and control rats for
percentage of basal diameter blockable with L-NNA (10-4mol/L): A2, P =0.35; A3, P =0.02; A4, P =0.49.228 B. VAN DAM et al.
Response to nitroprusside under L-NNA










FIGURE 4 Response to exogenous NO in different orders of arterioles. Inside diameters, both expressed as absolute diameters
(tm) and as percentage of the passive diameter (i.e., after 10-4mol/L adenosine; set at 100%), of A2A4 arterioles in the
spinotrapezius muscle after superfusion of 10-4mol/1 NP during blockade of NO production with L-NNA (10-4mol/L) in
control (open plots) and diabetic rats (DM; filled plots); box-and-whisker plots. P-values for the comparison between DM
and control rats for absolute inside diameters: A2, P 0.02; A3, P 0.83; A4, P 0.41. P-values for the comparison betweenDM
and control rats for relative inside diameters: A2, P 0.02; A3, P =0.17; A4, P =0.66.
no longer significantly different between dia-
betic and control rats in these arterioles (data
not shown), suggesting that an increased basal
production of NO could still cause a further
increase in diameter in diabetic rats after either
adenosine or acetylcholine.
DISCUSSION
Induction of diabetes mellitus by streptozotocin
treatment in rats is an accepted model of human
type 1 diabetes. I161 This model allowed us to
investigate differential microcirculatory changesNO ACTWITY AND SENSITWITY 229
in DM, which cannot be studied in man. We
intended and achieved incomplete destruction
of pancreatic beta-cells and therefore the dia-
betic rats had some residual insulin production
and thus a comparatively moderate hyper-
glycemia ( 20 mmol/1). [15, 27]
Using intravital microscopy, we found an
increase in basal diameter in A3 and A4, but not
in A2 arterioles after 6 weeks of STZ-induced
diabetes mellitus (Fig. 2). There was a greater
change in diameter after L-NNA in the diabetic
rats as compared to the control rats, especially
in A3 arterioles (Fig. 3). This suggests that the
increase in basal diameter observed in diabetic
rats is at least partially due to an increased con-
tribution of endogenous NO to basal diameter
in the A3 arterioles. Although NO production
was increased significantly in A3 arterioles only,
it cannot be excluded that also in A2 and A4
arterioles there was some increase inNO produc-
tion in diabetic rats. These findings support the
hypothesis of Williamson et al., that an increased
NO production occurs in the early phase of
DM. I2sl An increased NO production was also
observed in the kidney of STZ rats. [29] HOW-
ever, several studies also report weaker relaxa-
tion responses to endothelium-dependentagents
after induction of diabetes with STZ. [30-33]
These differences might be explained by varia-
tions in experimental set-up, the type of endothe-
lium-dependent relaxation response that was
investigated, the type of vessel, the duration of
diabetes and differences in the elevation in
glucose levels that were obtained in STZ rats.
Although NO has been indicated as an anti-
atherosclerotic molecule, [34, 35] several studies
provide evidence that the increase inNO activity
we observed in the early phase of STZ-induced
diabetes may be a mediator of vascular damage.
An increased NO synthase activity can induce
chemical injury to the vessel wall via the pro-
duction of peroxynitrite, a toxic radical. [36-39]
An enhanced NO activity in the early phase of
diabetes which preceded impaired function in
the later phase was described by Pieper et al.
Moreover, they showed that NOX-101, a sca-
venger of NO, prevented endothelial dysfunc-
tion in STZ-induced diabetic rats. [391 However,
it has also been shown that chronic treatment
with anNO donor can ameliorate diminished re-
sponses to ACh in aorta and kidney vasculature
caused by streptozotocin.
[401 Whether the ob-
served increase in basal NO activity shown in
our model also causes microvascular damage
in a later phase of the disease needs further
elucidation.
In the control rats, the maximal responses to
ACh were comparable to those found by other
investigators using the same spinotrapezius
muscle preparation. 151 In the diabetic rats of
the present study, ACh still had the capacity to
dilate the arterioles maximally after 6 weeks of
diabetes. The maximal vasodilation caused by
ACh could only partly be blocked by L-NNA,
indicating that in this study the maximal
response to ACh was mainly independent from
nitric oxide production. Although ACh is often
used as a means to measure stimulated NO-
mediated vasodilatation it is well known that
ACh not only releases NO, but also causes an
increased production of the vasodilator endo-
thelial derived hyperpolarizing factor (EDHF)
and prostacyclin (PGI2) as well as several vaso-
constricting mediators. Streptozotocin diabetes
can cause an increase in ACh-induced PGI2 pro-
duction.
[40] As we focussed on possible altera-
tions in NO production and sensitivity we
cannot exclude that inside diameter differences
between control and diabetic rats in this study
are partly caused by changes in production of
other vasorelaxing or constriciting agents.
After blocking endogenous NO production,
we found a further difference between diabetic
and control rats: a decrease in the effect of
10-4mol/L nitroprusside in diabetic rats in the
A2 arterioles. Nitroprusside, as a direct donor
of NO to smooth muscle cells, is often used to
establish whether the response of smooth mus-
cle cells to NO is still intact. When the NP effect
is impaired, a defect in the mechanism by which230 B. VAN DAM et al.
NO stimulates the smooth muscle cells through
activation of guanylate cyclase and production
of cGMP is assumed. I411 The dose of nitro-
prusside we used (10-4mol/L), which was
high enough to cause maximal dilatation in the
arcade arterioles (A2) of control rats, was not
able to cause maximal dilatation in the same
order arterioles of diabetic rats. The cause of
this phenomenon is presently unclear, but it
is possible that the mechanism via which NO
activates guanylate cyclase in smooth muscle
cells is impaired after 6 weeks of STZ induced
diabetes. An argument in favor of this hypoth-
esis is the fact that A2 arterioles contain a
relatively high amount of smooth muscle cells.
An early increase in NO production may cause a
decreased expression of guanylate cyclase or a
desensitisation of guanylate cyclase.
[42]
In this study we investigated changes in
arteriolar reactivity after 6 weeks of STZ
induced diabetes. We found an increased basal
diameter in A3 and A4 arterioles and an un-
changed diameter in A2 arterioles. This would
be expected to result in a decreased pressure
gradient from A2 arterioles to precapillary arte-
rioles and thus in an elevated capillary pressure,
which indeed has been observed in patients
with type 1 diabetes mellitus.
[43]
There are several possible causes for the
changes in arteriolar reactivity in streptozotocin
diabetes. Firstly, moderate hyperglycemia can
cause changes in oxidative stress and increased
production of reactive glycation products. Both
for acute and chronic hyperglycemia it has been
shown that hyperglycemia increases NO pro-
duction and decreases the bioavailability of
NO.[44"45] Secondly, changes in arteriolar reac-
tivity might be primarily due to the decreased
delivery of nutrients to the muscle cells, causing
an autoregulatory dysfunction leading to vaso-
dilatation. I2-41 Thirdly, streptozotocin-induced
diabetes causes marked atrophy of hindlimb
skeletal muscles, which is accompanied by a
relative increase in flow capacity per tissue
mass. [46] It cannot be excluded that the changes
in arteriolar reactivity that were observed in
this study might have been partly caused by
an attenuation of muscle development that is
caused by STZ diabetes, but that is also part of
the clinical picture of type 1 diabetes. However,
the exact mechanism via which STZ diabetes can
cause the observed changes in arteriolar reactiv-
ity is beyond the scope of this study.
In conclusion, after 6 weeks of STZ-induced
diabetes in rats, we found an increased basal
diameter of small transverse arterioles of the
spinotrapezius muscle but not of the larger
arcade arterioles. There was a significantly in-
creased contribution of endogenous NO to basal
tone in A3 arterioles. The reactivity to exogenous
NO was impaired in A2, but not in A3 and A4
arterioles. Thus, this study suggests a role of
alterations in NO activity and sensitivity to NO
in the pathogenesis of diabetic microvascular
complications. Furthermore, our results show
that these diabetes-induced changes are ana-
tomically specific and, for arterioles, depend on
their position within the vascular tree.
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